Antabio has received a €4.7 Million Wellcome Trust Seeding Drug Discovery Award to support the development of a novel, safe and efficacious pan-inhibitor of bacterial metallo ß-lactamases, from current leads to preclinical candidate nomination.
Antabio has established an industrial technology platform dedicated to the discovery, evaluation and development of new combination and/or adjunctive antibiotic therapies.
Antabio is a France-based biopharmaceutical company dedicated to the discovery and development of first-in-class molecule compounds to treat severe hospital- and community-acquired infections caused by multi- and pan-drug resistant bacterial pathogens.
Antabio uses its patented technology, unique antibacterial discovery experience, and partnering-oriented business strategy to advance novel drugs that will offer a synergistic solutions to the shortfall of the currrent antibacterial arsenal.
Antabio awarded EUR 742,000 (USD 1,02 million) funding from Bpifrance to support the discovery of New Gram-Negative Anti-Infective Agents13/11/2013
Antabio and Bpifrance, the French public investment bank, announce that Antabio will receive EUR 742,000 (USD 1,02 million) in funding from Bpifrance to support the discovery, evaluation and development of new adjunctive antibiotic therapies. Read more
Antabio is pleased to announce that the company has appointed Mr. Gordon Waldron as new non-executive member of its Strategic Advisory Board. Gordon was the Vice President and Chief Financial Officer of the antibacterial drug discovery company Novexel Read more